{'fraction_non_alphanumeric': 0.023376623376623377, 'fraction_numerical': 0.02142857142857143, 'mean_word_length': 4.75, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CA-125: A potential screening tool for benign and malignant lesions in post-menopausal females presenting with adnexal mass at a tertiary care center in Saurashtra region

Background: Among women ovarian cancer the seventh-most common cancer and the eighth-most common cause of death from cancer. The typical age of diagnosis is 63. When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses. With the increasing load of patients in our setup it is essential to look for serum tumor markers which can help narrow down patients who require attention. CA-125 is the most frequently used biomarker for ovarian cancer detection. Not only CA-125 helps to screen patients in certain age group but also monitor therapy. This study aims to find out the use of CA-125 as a potential tool for screening ovarian cancer in certain age groups in conjunction with other findings. Materials and Method: This is a retrospective study which entails assessment of serum CA- 125 level in post-menopausal females (>45 years old female considered in this study) who presented with a history of adnexal mass. Result: CA-125 has a sensitivity of 90.55% and specificity of 74.28% in detecting ovarian malignancies in post-menopausal females. Conclusion: Within the paradigm of this study CA-125 serves as a good marker for screening of postmenopausal females who present with adnexal mass and it is best used in conjunction clinical findings and with other diagnostic modalities like ultrasonography.